Sergio Bracarda
Impact in
- Pulmonary and Respiratory Medicine top 0.05%
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Renal cell carcinoma treatment 91
- Prostate Cancer Treatment and Research 51
- Prostate Cancer Diagnosis and Treatment 14
- Oncology 52
- Cancer Immunotherapy and Biomarkers 23
- Cancer survivorship and care 7
- Co-authors
- Bernard J. Escudier (22 shared papers)Alain Ravaud (15 shared papers)Camillo Porta (31 shared papers)Stéphane Marie. Oudard (13 shared papers)Robert John Motzer (10 shared papers)Viktor Grünwald (11 shared papers)Thomas E. Hutson (9 shared papers)Robert A. Figlin (5 shared papers)
- Journals
- Annals of Oncology (32 papers)European Journal of Cancer (18 papers)Critical Reviews in Oncology/Hematology (11 papers)The Lancet Oncology (9 papers)European Urology (9 papers)
- Partner nations
- ItalyUnited StatesFrance
In The Last Decade
Sergio Bracarda
234 papers receiving 20.8k citations
Sergio Bracarda's Hit Papers
Peers
Comparison fields: 5 of 117
- Pulmonary and Respiratory Medicine 11.6k
- Oncology 5.8k
- Cancer Research 713
- Surgery 1.9k
- Molecular Biology 1.9k
Countries citing papers authored by Sergio Bracarda
This map shows the geographic impact of Sergio Bracarda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergio Bracarda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergio Bracarda more than expected).
Fields of papers citing papers by Sergio Bracarda
This network shows the impact of papers produced by Sergio Bracarda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergio Bracarda. The network helps show where Sergio Bracarda may publish in the future.
Co-authors
The 25 scholars most cited alongside Sergio Bracarda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 244 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2018 | 3686 |
| 2 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Hit paper breakdown → | 2008 | 2537 |
| 3 | Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Hit paper breakdown → | 2007 | 1840 |
| 4 | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial Hit paper breakdown → | 2017 | 1382 |
| 5 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma Hit paper breakdown → | 2018 | 1023 |
| 6 | Phase 3 trial of everolimus for metastatic renal cell carcinoma Hit paper breakdown → | 2010 | 981 |
| 7 | Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial Hit paper breakdown → | 2019 | 826 |
| 8 | Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival Hit paper breakdown → | 2010 | 681 |
| 9 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Hit paper breakdown → | 2019 | 657 |
| 10 | Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Hit paper breakdown → | 2009 | 498 |
| 11 | Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2021 | 269 |
| 12 | 2018 | 262 | |
| 13 | Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2023 | 248 |
| 14 | 2020 | 214 | |
| 15 | 2011 | 202 | |
| 16 | 2016 | 182 | |
| 17 | 2019 | 158 | |
| 18 | 2015 | 152 | |
| 19 | Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Hit paper breakdown → | 2023 | 150 |
| 20 | 2017 | 141 |
About Sergio Bracarda
Sergio Bracarda is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Cancer Research and Genetics, having authored 244 papers that have together received 21.3k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (91 papers), Prostate Cancer Treatment and Research (51 papers), Cancer Immunotherapy and Biomarkers (23 papers), Bladder and Urothelial Cancer Treatments (23 papers), Prostate Cancer Diagnosis and Treatment (14 papers), Nausea and vomiting management (10 papers), Cancer survivorship and care (7 papers) and BRCA gene mutations in cancer (7 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (11.6k citations), Oncology (5.8k citations), Cancer Research (713 citations), Surgery (1.9k citations) and Molecular Biology (1.9k citations). Sergio Bracarda has collaborated with scholars based in Italy, United States and France. Frequent co-authors include Bernard J. Escudier, Alain Ravaud, Camillo Porta, Stéphane Marie. Oudard, Robert John Motzer, Viktor Grünwald, Thomas E. Hutson, Robert A. Figlin, John A. Thompson and Andrea Kay. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Critical Reviews in Oncology/Hematology, The Lancet Oncology and European Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.